• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Closed-loop insulin delivery systems shine at annual diabetes meeting

June 26, 2018 By Sarah Faulkner

Diabeloop logo

Diabeloop touts 12-week, real-world study of closed-loop system

Diabeloop reported this week that people with Type I diabetes who used its DBLG1 closed-loop insulin delivery system in an at-home setting spent a greater percentage of time in the target blood glucose range, with fewer hypoglycemic events, compared to those who use an open-loop system.

The 12-week study, which enrolled 68 adults with Type I diabetes, randomly assigned participants to two groups – 33 people used the DBLG1 system and 35 people used their usual pump and glucose sensor.

According to Diabeloop, people using the DBLG1 system spent 69.3% of the time in the target blood glucose range of 70-180 mg/dl compared to 56.6% of people using an open-loop system. People in the DBLG1 group spent 2% of the time in hypoglycemia, compared to 4.5% for the open-loop group.

“The DBLG1 is a powerful and customizable algorithm system for Type I diabetes treatment that may enable patients to significantly and durably reduce their glucose levels without an increase in hypoglycemic events,” lead author Dr. Sylvia Franc said in prepared remarks. “The results of our study confirm in real life, over a 12-week period, the positive results previously observed in an inpatient setting.”

Were you at this year’s ADA meeting? Drop me a note in the comments – what major themes emerged for you? 

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Pages: Page 1 Page 2 Page 3 Page 4

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Diabeloop, Insulet, Medtronic

IN CASE YOU MISSED IT

  • Tandem wins FDA nod to pair Mobi pump with Android smartphones
  • The top CGM stories of 2025
  • Billie Jean King supports Medtronic Diabetes awareness initiative
  • Tandem stock rises after hours on Q3 beats, record sales
  • Insulet leadership talks patch pump competition, expanding type 2 diabetes market

Reader Interactions

Comments

  1. Carolyn says

    August 23, 2018 at 3:26 am

    I am an omnipod user. Just talked to their customer service representative, who knows of no plans to connect a CGMS to an Omnipod.

    Has Insulet’s Omnipod Eros, https://www.drugdeliverybusiness.com/insulet-settles-shareholder-suit-over-omnipod-eros-device/, kept Insulet from pursuing a closed loop system?

    ‘Insulet, touted data at this year’s meeting demonstrating the benefits of their systems that connect glucose monitoring data and insulin dosing’

    • Sarah Faulkner says

      August 23, 2018 at 7:29 am

      Hi Carolyn, thanks for your message! Insulet is developing a system, called the Omnipod Horizon, that is designed to automate insulin delivery. Here’s some more information from Insulet’s CEO: https://www.drugdeliverybusiness.com/how-insulets-ceo-plans-to-create-a-billion-dollar-business/

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS